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Abstract 
 
Objective/Background: CBT for insomnia (CBT-I) is useful for many. It is currently 
unknown if those with sub-threshold insomnia also benefit. Here we assessed whether CBT-I 
is both feasible and acceptable in participants with sub-threshold insomnia. The primary aims 
were to evaluate participation rates and treatment acceptability, and to establish an effect size 
for symptom improvement. 
 
Patients/Methods: A total of 199 female participants (Mage 20 ± 5 years) took part. Following 
baseline assessments, participants were randomly allocated to either a 6-week digital CBT-I 
intervention or a 6-week session control group receiving puzzles. Additional assessments 
were performed 3-weeks, 6-weeks, and 6-months later. 
 
Results:  Participation in each survey wave did not differ between the groups (ps > .140), 
though adherence to weekly tasks was lower in the CBT-I group, p = .02. Treatment 
acceptability was high (M (SD) = 33.61 (4.82), range 6 – 42). The CBT-I group showed 
greater improvement in insomnia symptoms at the end of the intervention compared to the 
control group (p = .013, d = 0.42), with significant variation in outcome (M = 4.69, SD = 
5.41). Sub-threshold participants showed a similar pattern of results, whilst those meeting 
insomnia criteria showed a smaller between-group difference. CBT-I led to improvements in 
anxiety, paranoia and perceived stress between baseline and end of intervention. Changes in 
insomnia symptoms were mediated by cognitions about sleep and somatic pre-sleep arousal. 
 
Conclusions: CBT-I provides a benefit even in sub-threshold insomnia. CBT-I may be useful 
as an early preventative intervention to tackle sleep problems before they manifest as chronic 
insomnia. 
 
Keywords 
 
cognitive behavioural therapy, insomnia, sleep complaints 
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1. Introduction 
 
Insomnia occurs frequently and causes a substantial burden to society (Kessler et al., 2011). 
Cognitive behavioral therapy for insomnia (CBT-I) has been shown to be a highly effective 
in reducing insomnia symptoms (Seyffert et al., 2016; Trauer, Qian, Doyle, Rajaratnam, & 
Cunnington, 2015; van Straten et al., 2018). As such, CBT-I is now the first-choice treatment 
for insomnia (Qaseem et al., 2016; Riemann et al., 2017). As well as reducing insomnia 
symptoms, CBT-I can also reduce non-insomnia complaints such as anxiety and depression 
symptoms, levels of paranoia, and hallucinatory experience (Freeman et al., 2017; Ye et al., 
2015). More generally, sleep-related quality of life and psychological well-being have been 
shown to be improved by CBT-I ( Espie et al., 2019).  
 
 Whilst it is clear that CBT-I is beneficial to those who already have a diagnosis of 
insomnia, it is unknown whether those without insomnia would also see benefits from CBT-I. 
Two previous studies have shown that even those with sub-threshold insomnia symptoms 
report poorer quality of life (including mental health difficulties) than those reporting no 
sleep problems at all (LeBlanc et al., 2007; Léger, Scheuermaier, Philip, Paillard, & 
Guilleminault, 2001). Given this, it is important to investigate whether CBT-I can lead to 
improvements in those who report sub-threshold insomnia. Furthermore, it is possible that 
being able to successfully administer CBT-I when only a few symptoms are present, could 
act as an important preventative measure against the development of more severe insomnia 
disorder.  
 
 Even though approximately 70% of patients show improvements with CBT-I, not 
everyone responds to treatment (Ritterband et al., 2017). Understanding moderators of 
treatment response will aid in identifying the best therapeutic solution for a given individual. 
Moderators of improvement in insomnia symptoms following CBT-I are still relatively 
unexplored (Luik, Kyle, & Espie, 2017). Accumulating evidence of genetic predictors of 
CBT outcome in a range of anxiety disorders and depression have been reported (Andersson 
et al., 2013, 2019; Bryant et al., 2010; Hudson et al., 2013; Lonsdorf et al., 2010), and holds 
promise for delivering a fuller understanding of psychopathology and the ability to tailor 
treatments to individuals (Beevers & McGeary, 2012). 
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 Detecting moderation, especially genetic moderators, requires a high amount of 
statistical power. Given recent developments of digital CBT-I platforms, administering CBT-
I to large genetically sensitive cohorts, such as twin studies, is now feasible. Twin pairs can 
be concordant or discordant for insomnia, meaning that some participants in large cohorts 
may not have insomnia diagnosis. Therefore, it needs to be established whether CBT-I leads 
to an improvement in insomnia symptoms in a sample where some participants report sub-
threshold symptoms. Furthermore, it is unknown whether such individuals would find a 
CBT-I intervention acceptable, and the extent to which there would be drop-out. Addressing 
these questions constitutes the primary aims of the present study.  
 
The overall aim of this work was to establish the feasibility of using CBT-I in a 
sample not specifically selected for insomnia disorder, in order to establish the effect size of 
symptom change following the intervention. We were interested in further understanding the 
usefulness of such an intervention for those with sub-threshold insomnia, and to enable the 
design and implementation of a large-scale twin study of symptom change following CBT-I. 
The specific aims were: 
 
1. Primary aim 1. Feasibility: Assess participant rates, adherence, and treatment 
acceptability throughout the study. 
2. Primary aim 2: Determine the effect size for the between group (CBT-I vs control) 
change in insomnia symptoms from baseline to post intervention. 
3. Secondary and exploratory aims: Exploratory analyses to investigate effect sizes for 
changes in other associated, non-insomnia, variables, and moderators and mediators 
of change. 
 
2. Methods 
 
2.1. Design 
 
For full details of the design of this feasibility study, see the study protocol (Denis et al., 
2017). The study timeline and flow of participants through the study is shown in Figure 1. 
Participants were recruited from three London universities. Inclusion criteria were: female, 
enrolled on a psychology degree at one of the study sites, and no previous experience with 
the intervention program. The decision to only include females was made on the basis that 
the recruitment pool was majority female so adding males would create heterogeneity 
 5 
without sufficient power to examine possible sex differences (Denis et al., 2017). There were 
no other specific inclusion or exclusion criteria. Recruitment involved advertising the study at 
the end of student lectures, and through e-mail lists. Participants wanting to take part were 
given a study information document and were given the option to ask the researchers any 
questions. After providing informed consent, participants completed a baseline assessment. 
 
 After the collection of baseline data, participants were randomly allocated to either 
the intervention (6-session digital CBT-I program) or control (6 sessions of online puzzles) 
group. The control was chosen on the basis that it took a similar amount of time each week as 
the intervention, was deemed cognitively engaging/demanding, and was not expected to 
improve insomnia symptoms. Randomization was performed using the blockrand package for 
R (Snow, 2013), stratified for age, baseline insomnia symptoms, and study site. Following 
allocation, participants completed three further online assessments. These were carried out 
online at 3 weeks (mid-intervention), 6 weeks (end of intervention), and 6 months after 
starting the intervention (follow-up). All assessment sessions were completed using the 
online survey platform Qualtrics. A total of 240 participants consented to take part in the 
study (meeting the enrolment estimate on the trial registration), with 199 completing the 
baseline assessment and being allocated to a group. The study received ethical approval from 
the Research Ethics and Integrity subcommittee at Goldsmiths, University of London 
(reference number: EA 1305). The trial was registered on clinicaltrials.gov (registration 
number: NCT03062891).  
 
2.2. Measures  
 
2.2.1. Primary outcome measures 
 
Treatment acceptability questionnaire (TAQ) (Hunsley, 1992) – A 6-item measure that 
assesses treatment acceptability of psychological treatments. Participants in the CBT-I group 
were asked the degree to which they found the treatment acceptable, ethical, effective, and 
about the likelihood of negative side effects on a 7-point scale. They were also asked two 
questions specifically about the nature of the therapist, regarding how knowledgeable and 
trustworthy participants judged him to be. All items were summed together to generate an 
overall score with a theoretical range of 6-42. A higher score equates to a more acceptable 
treatment.  
 6 
 
Sleep condition indicator (SCI) (Espie et al., 2014) – In this 8-item questionnaire, participants 
consider a typical night in the last month and rate various aspects of their sleep. Scores can 
range between 0-32. Higher scores indicate fewer insomnia symptoms, and scores <= 16 
indicate probable insomnia disorder. The SCI has a reliable change index (RCI) of 7, 
suggesting that a change of 7 or more points is a meaningful improvement (Espie et al., 
2018). 
 
2.2.2. Secondary and exploratory measures 
 
The following measures were included as associated outcome measures, and potential 
moderators and mediators. A full description can be found in the study protocol (Denis et al., 
2017): Anxiety symptoms (state trait anxiety index; Spielberger, Gorsuch, Lushene, Vagg, & 
Jacobs, 1983); depression symptoms (mood and feelings questionnaire; Angold et al., 1995); 
ADHD symptoms (ADHD symptoms questionnaire; Gregory, Agnew-Blais, Matthews, 
Moffitt, & Arseneault, 2017); psychotic experiences - paranoia, hallucinations, and cognitive 
disorganization (specific psychotic experiences questionnaire; Ronald et al., 2014); positive 
mental health (positive mental health scale; Lukat, Margraf, Lutz, van der Veld, & Becker, 
2016); perceived life stress (perceived stress scale; Cohen, Kamarck, & Mermelstein, 1983); 
threatening life events (list of threatening experiences; Brugha, Bebbington, Tennant, & 
Hurry, 1985; Coddington, 1983); general sleep quality (Pittsburgh sleep quality index; 
Buysse, Reynolds, Monk, Berman, & Kupfer, 1989); dysfunctional beliefs about sleep 
(Dysfunctional beliefs and attitudes about sleep questionnaire; Espie, Inglis, Harvey, & 
Tessier, 2000); somatic and cognitive pre-sleep arousal (Pre-sleep arousal scale; Nicassio, 
Mendlowitz, Fussell, & Petras, 1985); sleep disturbances typically related to trauma (PSQI 
addendum; Germain, Hall, Krakow, Katherine Shear, & Buysse, 2005); and chronotype 
(Munich chronotype questionnaire; Roenneberg, Wirz-Justice, & Merrow, 2003). 
 
Scale reliabilities are displayed in Supplementary Table 1. Full information about 
the measures administered at each wave can be found in the published study protocol (Denis 
et al., 2017). 
 
Groups 
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2.3. Intervention: Digital CBT-I 
 
Participants received 6 weekly CBT-I sessions delivered by an animated ‘virtual therapist’ 
via the online platform ‘Sleepio’. The program comprised a fully automated media-rich web 
application. It is driven dynamically by baseline, adherence, performance and progress data, 
and provides additional access to elements such as an online library with background 
information, a community of fellow users and support, prompts and reminders sent by email. 
The Sleepio program covers behavioral (e.g., sleep restriction, stimulus control) and 
cognitive (e.g., putting the day to rest, thought restructuring, imagery, articulatory 
suppression, paradoxical intention, mindfulness) strategies, as well as additional relaxation 
strategies (progressive muscle relaxation and autogenic training) and advice on lifestyle and 
bedroom factors (sleep hygiene).  As part of the intervention, participants filled in a daily 
sleep diary. For more details see elsewhere (Espie et al., 2012). The intervention was based 
on a previously validated manual (Espie et al., 2007, 2008; Espie, Inglis, & Harvey, 2001). 
Sleepio has been shown to improve sleep and associated daytime functioning in adults with 
insomnia complaints (Bostock, Luik, & Espie, 2016; Cheng et al., 2018; Espie et al., 2012, 
2019; Freeman et al., 2017). 
 
2.4. Control: Puzzles 
 
Participants in the control group were sent weekly puzzles to complete using Qualtrics. Each 
puzzle was designed to be cognitively engaging, and time taken to complete a puzzle was 
matched as closely as possible to the time taken to complete one session of digital CBT-I. 
Puzzles were sent directly to participants via automated distribution emails sent at 7-day 
intervals. In order to track whether participants were completing the puzzles, they were 
required to enter their participant ID number at the start of each puzzle. The types of puzzles 
administered to participants included word searches, crosswords and lateral thinking 
problems. 
 
2.5. Statistical analysis 
 
The primary aim of the study was to estimate feasibility parameters, estimate the variability 
in outcome between treatment groups and effect sizes from the group differences in mean 
outcome. Statistical analysis was based on the intention to treat principle with participants 
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analysed according to the treatment group to which they were assigned. Treatment 
differences were calculated at both end of intervention and follow-up, with end-of-
intervention being the main timepoint of interest.  
 
2.5.1. Primary outcomes 
 
Participation rate was assessed as the proportion of participants who completed each survey. 
Adherence was assessed as the proportion of participants who completed each weekly task. 
Whilst the focus was on participation in the intervention group, comparisons to the control 
group were made using chi-square. Ninety-five percent confidence intervals around the 
proportions were obtained using the proportion command in STATA, and reflects with 95% 
confidence where the population proportion lies (StataCorp, 2013). Mean treatment 
acceptability score, measured during the end of intervention survey, was used to measure 
treatment acceptability.  
 
The Sleep Condition Indicator was a primary outcome of interest. Variability of the 
treatment difference was calculated via the pooled standard deviation across group for change 
in score from baseline to end of treatment. This was then used to estimate effect sizes 
(Cohen’s d, plus its 95% confidence interval) of the between group difference in insomnia 
symptoms change (from baseline to end of intervention) (the primary outcome). An 
independent samples t-test was used to test statistical significance. Cohen’s U3, percentage 
overlap of change scores between the two groups, and the probability of superiority were 
calculated to facilitate interpretation of the effect size (see study protocol for more 
information, Denis et al., 2017).  
 
To investigate whether these changes were driven mainly by participants with the 
poorest baseline sleep problems, we also looked at effect size separately for those whose 
baseline insomnia symptoms were either above or below the insomnia threshold. 
Additionally, we examined the change in percentage of participants who went from meeting 
threshold criteria for insomnia to not. The percentage of participants whose change scores 
were equal or higher than the sleep condition indicator’s reliably change index were also 
calculated. Statistical significance was assessed using chi-square. 
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Finally, the relative effects of group, time, and the group * time interaction were 
assessed using a generalized estimating equation. Insomnia symptoms at mid- and end of 
intervention were entered as dependent variables. Group (control group set as reference), 
time (mid intervention set as reference), and the group * time interaction were entered as 
predictors. Baseline insomnia symptoms and age were entered as co-variates.  
 
2.5.2. Secondary and exploratory outcomes 
 
Changes in associated variables were assessed using generalized estimating equation (GEE) 
models. For each variable, a GEE model was fitted using the associated variable score 
assessed at mid- and end-of-intervention as dependent variables. Predictors were group 
(control group set as reference), time (mid-intervention set as reference), and the group * 
time interaction. Baseline score on the associated variable, baseline insomnia symptoms, and 
age were entered as co-variates. A total of 8 GEE models were run, using the following 
dependent variables: anxiety symptoms, depression symptoms, ADHD symptoms, 
experiences of paranoia, experiences of hallucinations, cognitive disorganization, positive 
mental health, and life stress. ADHD and measures of paranoia, hallucinations, and cognitive 
disorganization were not assessed mid-assessment. As such, for these measures, no main 
effect of time or group * time interaction could be calculated. Co-efficient size and 95% CI 
were taken as the measure of effect size.  
 
Moderators of treatment outcome were assessed using multiple regression models. 
For each potential moderator, a regression model with insomnia symptoms at the end of 
assessment was included as the dependent variable, and group, moderator, and group * 
moderation interaction as predictors. Age and baseline insomnia symptoms were controlled 
in each model. The standardized co-efficient and 95% CI for each group * moderator 
interaction was taken as an estimate of the moderator’s effect size. A total of 10 regressions 
were performed, for each of the following potential baseline moderators (insomnia 
symptoms, anxiety symptoms, depression symptoms, ADHD symptoms, experiences of 
paranoia, experiences of hallucinations, cognitive disorganization, positive mental health, life 
stress, and exposure to potential threatening life events). 
 
Given that individual moderators often show a small effect size, we also calculated a 
combined moderator term using the method described by Kraemer (Kraemer, 2013; Wallace, 
 10 
Frank, & Kraemer, 2013). A regression of end of assessment insomnia symptoms on group, 
the combined moderator, and the group * combined moderator interaction was run. This 
analysis was done after the individual moderator analyses. Bootstrapped mediated 
regression models (5000 repetitions) were used to test for mediators of treatment outcome. 
For each potential mediator, insomnia symptoms at the end of treatment was used as the 
dependent variable. The predictor variable was group, with age, baseline mediator score, and 
baseline insomnia symptoms as co-variates. Six models were run, with the following 
variables (all measured at the end-of-intervention assessment) as mediators: general sleep 
quality, cognitions about sleep, somatic pre-sleep arousal, cognitive pre-sleep arousal, 
trauma-related sleep disturbances, and chronotype. 
 
All secondary and exploratory analyses were performed using the full sample. As we 
were primarily interested in effect size, reported p values are uncorrected for multiple 
comparisons. 
 
2.5.3. Missing data 
 
Given there was participant drop-out through the trial we used a 2-step process which 
assumed data were missing at random. A binary variable was created to indicate whether data 
were missing or not. Predictors of missing data at the end of intervention assessment were 
then examined using logistic regression. All baseline measures and treatment acceptability at 
mid-intervention were investigated as potential predictors in the same regression model. In 
the second step, multiple imputation was used to estimate missing data, carried out in 
STATA using an imputation-chained-equations algorithm. Significant predictors of 
missingness were included in the imputation model. A total of 25 imputed datasets were 
created. All variables that had missing data of <30% and were deemed missing completely at 
random or missing at random were entered into the multiple imputation algorithm. 
 
2.6. Deviations from protocol 
 
In our original protocol, we had planned to perform GEE models to assess predictors of 
treatment outcome (Denis et al., 2017). However, on the advice of statisticians involved in 
the analyses, we changed these analyses to multiple regressions with SCI scores at a single 
timepoint (end of intervention). This change was made to simplify the interpretations of 
 11 
results and to increase statistical power to address our questions. Additionally, we originally 
planned to analyze data from the 6-month follow-up assessment. However, due to a high 
drop-out at that assessment, we focused our analyses on the end-of-intervention assessment 
instead. For transparency, analyses focusing on the 6-month follow-up are presented as 
Supplementary results. Finally, we conducted post-hoc sub-group analyses on our primary 
outcomes separately for participants who were either above or below the SCI threshold for 
insomnia at baseline. These analyses were not initially planned but were added to allow us to 
check whether any changes identified might be driven by those with insomnia reporting a 
reduction in symptoms over time. 
 
3. Results 
 
Participant characteristics are shown in Table 1. Descriptive statistics for variables at each 
wave are shown in Table 2. At baseline insomnia symptom scores ranged from 3-31, 
meaning that all participants endorsed some sleep complaints. Lower positive mental health 
and higher perceived stress at baseline were found to significantly predict missing data at the 
end of the intervention (p < .05), and were included in the imputation model. 
 
3.1. Primary outcomes 
 
Participation and adherence rates at each wave are shown in Table 3. For participation rates, 
there were no significant differences between groups at any of the waves (all χ2 (1) > 1.85, p 
> .140). With regards to adherence, significantly more participants in the control group 
completed all six weekly sessions (puzzles) than in the intervention group (CBT-I; χ2 (1) > 
4.82, p = .028). For both participation and adherence, there were no differences between 
those above the threshold for insomnia, and those below it (all ps > .342). Mean treatment 
acceptability score for the CBT-I program was 33.61 (SD = 4.82, min = 22, max = 42). 
Responses to each item are shown in Figure 2. There were no differences in treatment 
acceptability between those who fell above or below the threshold for insomnia at baseline 
(Mdiff = 0.32, SD = 5.30, p = .829, d = 0.06). 
 
 Insomnia symptoms scores at each assessment are shown in Figure 3, and a detailed 
summary of the effect of group on insomnia symptoms are displayed in Table 4. At the end 
of the intervention, the CBT-I group showed a larger improvement in insomnia symptoms 
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than the control group; t (140) = 2.51, p = .013, d = 0.42). Histograms showing variation in 
SCI change scores for the two groups are shown in Supplementary Figure S1). Additional 
effect size measures (Cohen’s U3, percent overlap, and probability of superiority) are shown 
in Table 4. We then looked at the effect of group separately for participants that either did 
not (n = 97) or did (n = 45) meet the threshold requirement for insomnia at baseline. For 
those that did not meet the criteria for insomnia, a similar group effect was found to when 
looking at the whole sample (t (95) = 2.49, p = .015, d = 0.51). The effect size was smaller 
for participants who did meet the criteria for insomnia at baseline (t (43) = 0.68, p = .497, d = 
0.21). 
 
 We then looked within each group (CBT-I or control) and compared change scores in 
those who did and did not meet insomnia criteria at baseline. Within the CBT-I group, there 
was a non-significant higher change in insomnia symptoms for those that did meet insomnia 
criteria at baseline (t (66) = 1.73, p = .087, d = 0.44). Within the control group, those who 
met insomnia criteria at baseline showed a significantly higher change in insomnia symptoms 
than those that did not meet criteria (t (72) = 2.26, p = .027, d = 0.59). 
 
 Additionally, within the CBT-I group, there was a significant reduction in the 
percentage of participants meeting the criteria for insomnia at the end of the intervention 
(36%), compared to baseline (17%); χ2 (1) = 6.00, p = .013. This change within the control 
group was not significant (end of intervention = 18%, baseline = 28%,; χ2 (1) = 2.69, p = 
.101). The between-group change was not significant – although there was a trend (χ2 (1) = 
3.77, p = .052). A significantly higher percentage of participants in the CBT-I group had 
change scores that met or exceeded the sleep conditional indicator’s reliable change index 
(35%) compared to the control group (17%); χ2 (1) = 6.23, p = .013. 
 
 A GEE model predicting change in SCI score from group, time, and group * time 
interaction showed a significant main effect of group, with a larger change in the intervention 
group compared to the control group (β = 1.94, 95% CI = 0.42 – 3.47, p = .013). Full model 
results are shown in Supplementary Table 2. 
 
Analyses were repeated for the 6-month follow-up assessment (see Supplementary 
results), with a similar pattern of findings being obtained. The between-group effect size at 
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6-month follow up was d = 0.44, with again the effect being larger in those who did not meet 
insomnia criteria at baseline (d = 0.55) compared to those who did (d = 0.11). 
 
3.2. Secondary and exploratory outcomes 
 
A set of GEE models were performed to examine whether group allocation predicted change 
in associated variables. Coefficients and 95% CI for the effect of group on the change in 
outcome variable are shown in Figure 4A, and full statistical information is shown in 
Supplementary Table 3. Anxiety symptoms (β = -2.57, 95 % CI = -4.97 – -0.25, p = .030), 
experiences of paranoia (β = -1.68, 95% CI = -3.31 – -0.07, p = .041), and perceived life 
stress (β = -2.07, 95% CI = -3.88 – -0.26, p = .025) all showed greater reductions in the 
intervention group compared to the control. When the 6-month follow up time point was also 
included, results were similar, but experiences of hallucinations showed a reduction in the 
intervention group, as opposed to paranoia (Supplementary Figure S2A). 
 
 Regression coefficients for each group * moderator interaction are shown in Figure 
4B, with full statistical information in Supplementary Table 4. None of the baseline 
variables were moderators of treatment outcome. At the 6-month follow-up, results were 
largely unchanged, however the combined moderator had 95% confidence intervals that did 
not cross zero (Supplementary Figure S2B). 
 
 To examine whether the effect of CBT-I on insomnia symptoms at the end of 
intervention was mediated by other sleep-related variables, a set of mediated regression 
models were run. Coefficients and 95% CIs for the indirect effect of each potential mediator 
on insomnia symptoms at the end of intervention are shown in Figure 4C. Supplementary 
Table 5 provides the full statistical information. Dysfunctional beliefs about sleep (β = 1.41, 
95% CI = 0.68– 2.39), and somatic pre-sleep arousal (β = 1.20, 95% CI = 0.47 – 2.31) 
showed indirect effects. At the six-month follow-up, only dysfunctional beliefs about sleep 
appeared to mediate the relationship (Supplementary Figure S2C). 
 
4. Discussion 
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This study aimed to assess the feasibility of administering CBT-I in a sample not selected for 
insomnia disorder, and establish effect sizes for changes in insomnia symptoms following a 
digital CBT-I intervention.  
 
 We found no significant differences in terms of participation rates between the two 
groups, although adherence to the tasks was significantly higher in the control group. In 
addition, there were no differences in terms of participation rate for those who met criteria for 
insomnia at baseline compared to those who did not. These results suggest that individuals 
who only endorse mild sleep complaints are willing to take part in a 6-week CBT-I program, 
and are no more likely to drop out than those with more severe complaints. They did however 
show lower adherence to the weekly tasks than the control group. Relatedly, participants 
rated CBT-I as highly acceptable. Again, no differences were found between those who either 
met or did not meet criteria for insomnia at baseline. Perhaps most interestingly, a large 
majority rated the treatment as being effective or highly effective. This is important because 
it suggests that in our sample of participants (including those with mild sleep complaints), 
they still believed that CBT-I was effective in improving their sleep. 
 
The effect size for the between-group change in insomnia symptoms at the end of the 
intervention was smaller than that found in studies using insomnia patients (Espie et al., 
2012). Additional metrics, such as Cohen’s U3 and the probability of superiority further 
illustrated the relatively small effect size obtained. Despite this, changes were still 
significantly larger in the CBT-I group than the control group, suggesting that CBT-I is 
effective at improving insomnia symptoms in a sample not selected for insomnia disorder. 
Additionally, for those that did not meet the threshold for insomnia disorder, we found a clear 
benefit of CBT-I on insomnia symptoms, meaning that improvement was not driven solely by 
those with the worst insomnia symptoms at baseline. An important implication of this finding 
is that even for those who only endorse sub-threshold symptoms of insomnia, CBT-I can still 
lead to improvements.  
  
We were surprised to discover that those who met threshold criteria for insomnia did 
not show greater improvements after CBT-I compared to the control task as the effectiveness 
of CBT-I for those with insomnia has been previously established (Seyffert et al., 2016). The 
reason for this finding is unclear. Whilst these participants did show a large improvement 
within the CBT-I group, they also showed a large improvement in the control group. This led 
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to a between-group effect size being approximately half that of those who did not meet the 
threshold criteria for insomnia at baseline. This also contradicts previous work finding lower 
insomnia severity to be associated with less successful treatment outcome (Yeung, Chung, 
Ho, & Ho, 2015). One possibility is that the insomnia symptoms reported at the beginning of 
the study did not necessarily reflect long-term issues (the SCI asks for symptoms over the 
past month), and hence there could have been a regression towards the mean over time in 
both the CBT-I and puzzles group. It is also noteworthy that the subgroup analyses were not 
pre-planned, and power was low when looking specifically at those with insomnia. This 
meant that statistical power may not have been adequate to detect the small effects found 
here.  
 
Even if CBT-I can improve insomnia symptoms in individuals whose symptoms are 
subthreshold, there is the practical question of why this is useful. If an individual thinks they 
suffer from sub-threshold insomnia, why should they receive CBT-I? Previous studies have 
shown that sub-threshold symptoms can have a negative effect on quality of life. As such, 
efforts to alleviate even minor complaints might result in a number of important benefits 
(Léger et al., 2001). Other studies of CBT-I have shown that it can bring numerous additional 
benefits, such as reduced anxiety, paranoia, and overall improvements in sleep-related quality 
of life and psychological well-being (Espie et al., 2019; Freeman et al., 2017; Ye et al., 
2015). Exploratory analyses in this study suggest that these additional benefits also extend to 
our sub-threshold insomnia symptom sample. We found greater reductions in anxiety 
symptoms, experiences of paranoia, and perceived life stress after CBT-I compared to the 
control group. These effects were obtained after controlling for baseline insomnia symptoms. 
This suggests that additional, non-insomnia, benefits of CBT-I can be gained even when 
insomnia symptoms themselves are sub-threshold. Finally, the CBT-I program may offer 
novel advice about how to improve insomnia symptoms in those whose symptoms are low. 
The tips offered in the CBT-I programme may be beneficial to these individuals. For 
example, we found that dysfunctional beliefs about sleep mediated the change in insomnia 
symptoms. This suggests that participants might have learned some important information 
about sleep that helped lead to overall improvements. Our finding that CBT-I is effective in 
reducing sub-threshold symptoms suggests that a brief intervention could act to prevent full 
insomnia disorder, by targeting symptoms early whilst they are still mild. Whilst our results 
speak to the idea that CBT-I is effective in treating symptoms when the severity is low, we 
did not examine the potential effects of symptom chronicity. Future research should 
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investigate whether CBT-I can improve sub-threshold symptoms when symptoms have been 
present for a long period of time, or if it is most effective when administered soon after 
symptom onset. 
 
A number of limitations should be considered. Our participants were female students 
of psychology, and it is conceivable that these participants may react differently to a 
psychological therapy than those from other groups and may rate the effectiveness of the 
therapy differently. The study only included females, so possible sex differences between 
females and males could not be investigated. Additionally, the control task may not have 
been ideally balanced to match the CBT-I. For instance, CBT-I required a daily sleep diary to 
be completed and the weekly sessions required participants to engage with the program. For 
the online puzzles, although they were matched for length to the weekly CBT-I sessions, 
there was not a daily task and it may have been easier for participants to complete them 
without as much engagement and attention. This would mean that those in the puzzles group 
had a lower participant burden as compared to those in the CBT-I group. This difference may 
potentially account for the lower adherence found in the CBT-I group. It is worth pointing 
out however that adherence in the present study was similar to other studies using the same 
CBT-I program (Freeman et al, 2019; Christensen et al, 2016). Finally, we did not collect any 
objective measurements of  sleep (e.g. actigraphy or polysomnography). Whether changes in 
objective sleep parameters (e.g. sleep onset latency, total sleep time, sleep efficiency) can be 
seen following CBT-I for sub-threshold insomnia is an exciting area for future research. 
 
A major reason for performing this feasibility study was to provide preliminary data 
that would be useful in the design of a large-scale study examining genetic and non-genetic 
predictors of response to CBT-I. To this end, the current study has given the following 
information about a sample not specifically selected for insomnia: 1 – CBT-I leads to greater 
improvements in insomnia symptoms compared to a control group, with a small-to-medium 
effect size; 2 – Additional, non-insomnia related improvements also occur, especially with 
regards to anxiety symptoms, experiences of paranoia, and perceived life stress; 3 – There 
was no clear evidence of specific moderators, though at 6-month follow-up the combined 
moderator 95% confidence intervals showed a non-zero crossing. This suggests a combined 
moderator may be important to assess in future work to establish whether this is a robust 
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finding, and; 4 – Preliminary evidence for mediation was found with regards to dysfunctional 
beliefs about sleep, and somatic pre-sleep arousal. 
 
In conclusion, this study has shown that participants who do not meet criteria for 
insomnia disorder still show a significant benefit of CBT-I, both in terms of insomnia 
symptoms themselves, and non-insomnia complaints including anxiety, paranoia, and 
perceived stress. Future work can utilize the results of this study to design a large-scale twin 
study of predicators of treatment outcome for CBT-I, looking at both genetic and non-genetic 
predictors. 
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Table 1 – Sample characteristics 
 Intervention Control 
 % M SD % M SD 
Age  19.73 2.94  20.22 5.69 
 
Ethnicity 
      
Arab 5.41   1.23   
Asian or Asian British 13.52   24.69   
Black or Black British 8.11   6.17   
Mixed ethnicity 8.10   9.87   
Other 6.76   6.17   
White 58.11   50.63   
 
Education 
      
At least GCSE (or equivalent) 98.65   100.00   
At least A-level (or equivalent) 98.31   89.09   
 
Employment 
      
Student 98.65   98.78   
Working full-time 1.35   0.00   
Working part-time 24.32   21.95   
Parent full-time 2.70   2.44   
On government benefits 1.22   1.35   
 
Marital status 
      
Legally separated/divorced 0.00   0.00   
Living with partner 2.44   5.41   
Married 0.00   1.22   
Single 90.24   82.43   
Other 6.10   12.16   
 
General health 
      
Excellent 16.05   13.70   
Very good 39.51   30.14   
Good 30.86   38.36   
Fair 12.35   15.07   
Poor 1.23   2.74   
       
Medication       
Prescription last 6 months (yes) 53.66   59.46   
Over-the-counter last 6 months (yes) 46.34   64.86   
 
Psychiatric diagnosis 
      
Lifetime diagnosis mood disorder 20.73   25.68   
Lifetime diagnosis schizophrenia 0   0   
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Note. M = Mean, SD = Standard deviation. Numbers for each construct may not sum to 100 due 
to missing data and possibility of selecting multiple options per construct. 
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Table 2 – Descriptive statistics for study variables at each wave 
Variable Intervention Control 
 
Baseline 
Mid-
intervention 
End of 
intervention 
Follow-up Baseline 
Mid-
intervention 
End of 
intervention 
Follow-up 
 M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) 
Insomnia 
symptoms 
19.70 (6.56) 22.50 (7.56) 24.52 (6.84) 24.27 (6.98) 20.22 (6.53) 21.04 (6.79) 22.78 (6.84) 22.02 (6.74) 
Anxiety 
symptoms 
49.93 (10.64) 46.68 (11.86) 44.57 (11.20) 45.02 (10.94) 47.53 (9.92) 46.58 (10.26) 45.32 (10.07) 45.92 (11.47) 
Depression 
symptoms 
10.09 (6.71) 8.70 (7.20) 6.91 (5.73) 7.09 (6.23) 8.65 (6.27) 8.00 (7.01) 6.51 (5.87) 8.27 (7.33) 
ADHD 
symptoms 
21.47 (11.69) - 16.51 (10.53) 16.91 (11.24) 22.09 (11.62) - 18.53 (13.33) 17.97 (12.83) 
Experiences of 
paranoia 
6.66 (5.76) - 4.59 (5.77) 4.69 (5.53) 6.43 (5.20) - 6.07 (5.92) 6.25 (5.66) 
Experiences of 
hallucinations 
3.03 (3.71) - 1.59 (3.24) 1.84 (3.64) 2.02 (2.55) - 1.31 (2.42) 2.25 (3.28) 
Cognitive 
disorganization 
3.19 (1.55) - 2.65 (1.89) 2.55 (2.03) 3.33 (1.55) - 3.07 (1.52) 2.43 (1.84) 
Positive mental 
health 
26.00 (6.44) 25.39 (7.01) 26.42 (6.18) 26.22 (6.86) 26.64 (5.76) 26.46 (5.69) 27.09 (6.09) 26.58 (6.63) 
Perceived life 
stress 
20.14 (6.82) 17.92 (8.24) 16.96 (6.57) 16.60 (7.87) 20.05 (6.12 19.14 (7.56) 17.71 (8.06) 17.95 (8.68) 
Threatening 
events 
2.57 (2.31) 0.80 (1.36) 0.63 (1.16) 0.73 (1.27) 2.72 (2.69) 1.08 (1.51) 0.74 (1.37) 1.13 (1.56) 
General sleep 
quality 
7.75 (3.39) 7.51 (3.53) 6.12 (3.06) 7.44 (3.78) 8.13 (3.52) 7.51 (3.30) 6.67 (3.44) 7.10 (3.66) 
Specific sleep 
disturbances 
3.66 (2.95) - 2.49 (3.17) 3.27 (3.77) 3.24 (3.17) - 2.32 (2.61) 3.10 (3.33) 
Somatic pre-
sleep arousal 
13.92 (5.46) 13.53 (5.98) 12.14 (4.15) 13.38 (5.67) 14.02 (5.57) 15.31 (6.29) 13.82 (5.70) 14.05 (6.58) 
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Cognitive pre-
sleep arousal 
21.81 (7.40) 19.23 (8.37) 17.59 (7.59) 18.22 (7.45) 21.39 (7.34) 19.63 (8.17) 18.27 (7.54) 20.18 (8.58) 
Dysfunctional 
beliefs about 
sleep 
55.95 (15.83) 22.09 (11.62) 22.09 (11.62) 22.09 (11.62) 52.30 (17.55) 50.39 (17.01) 48.65 (19.95) 22.09 (11.62) 
Chronotype 07:44 (01:40) - 07:47 (01:30) 06:56 (01:43) 07:10 (01:58) - 07:46 (01:42) 07:50 (01:42) 
Treatment 
acceptability 
- 34.12 (4.15) 33.24 (5.56) - - - - - 
Note. M = Mean, SD = Standard deviation. For all measures, a higher score indicates more symptoms, with the exception of insomnia 
symptoms, where a higher score indicates lower symptoms.. A higher positive mental health score indicates better positive mental health. 
Chronotype is estimated based on the midpoint between sleep onset and sleep offset on work free days, corrected for sleep debt accumulated 
over the work week. A higher treatment acceptability score indicates higher treatment acceptability.
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Table 3 – Participations rates and adherence 
 Intervention Control  
 % 95% CI % 95% CI sig 
Participation      
Mid-intervention assessment 69 59; 77 74 65; 82 .676 
End-of-intervention assessment 68 58; 76 78 69; 85 .408 
Six-month follow-up 47 36; 55 62 52; 71 .150 
      
Adherence      
Completed all 6 weekly tasks 57 44; 69 83 73; 91 .028 
Note. CI = Confidence interval, sig = chi-square statistical significance.
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Table 4. Effects of CBT-I on insomnia symptoms 
 
 Intervention Control Between group sig 
 M 95% CI  M 95% CI  p d 95% CI 
Change in insomnia symptoms (full sample) 4.69 3.82; 5.99  2.34 1.00; 3.67  .013 0.42 0.08; 0.75 
Change in insomnia symptoms 
(did not meet insomnia threshold at baseline) 
3.84 2.51; 5.16  1.44 0.08; 2.80  .015 0.51 0.10; 0.91 
Change in insomnia symptoms 
(did meet insomnia threshold baseline) 
6.16 3.37; 8.94  4.75 1.46; 8.03  .497 0.21 -0.79; 0.38 
   Within 
group sig 
  Within  
group sig 
   
 % 95% CI p % 95% CI p p   
Change in % meeting insomnia threshold 52 40; 63 .013 34 53; 84 .101 .052   
% of change scores meeting exceeding RCI 35 23; 46 <.001 17 8; 25 .015 .013   
          
Additional effect size quantifications          
 %         
Cohen’s U3 66         
% overlap of change scores between groups 83         
Probability of superiority 62         
Note. M = Mean, CI = Confidence interval, RCI = Reliable change index. Note that positive change values indicate an improvement (i.e. fewer)  
in  insomnia symptoms.
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Figure 1. Flow of participants through the study
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Figure 2. Treatment acceptability. A – Acceptable, responses range from 1 (Very 
unacceptable) to 7 (Very acceptable). B – Ethical, responses range from 1 (Unethical) to 7 
(Fully ethical). C – Effective, responses range from 1 (Very ineffective) to 7 (Very effective). 
D – Side effects, responses range from 1 (Very likely) to 7 (Very unlikely). E – 
Knowledgeable, responses range from 1 (Not knowledgeable) to 7 (Very knowledgeable). F 
– Trustworthy, responses range from 1 (Not trustworthy) to 7 (Very trustworthy). 
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Figure 3. SCI scores at each assessment. Solid lines represent scores across the full sample. 
Dashed and dotted lines show scores for participants above and below the threshold for 
insomnia respectively. Error bars indicate the standard error.
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Figure 4. Changes in associated variables, moderation, and mediation results. Control group 
is always used as the reference. A – Changes in associated variables: Standardized 
coefficients and 95% confidence intervals for the effect of group for each associated variable 
on the change in insomnia symptoms from baseline to end-of-intervention. B – Moderation: 
Standardized coefficients and 95% confidence intervals for each of the individual group * 
baseline predictor interactions and the group * combined moderator interaction for each 
potential moderator of insomnia symptoms at end-of-intervention. C – Mediation: 
Standardized coefficients and bias-corrected 95% confidence intervals for each potential 
mediator of insomnia symptoms at end of intervention. 
 
